NSE: NATCOPHARM | BSE: 524816

Mid-range Performer

Download real time

828.65 -9.65 (-1.15%)

32.45% Fall from 52W High

471.0K NSE+BSE Volume

NSE 04 Sep, 2026 3:31 PM (IST)

14,841.9

Market Cap

High in industry

Beta 1Year

High Volatility

Natco Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for NATCOPHARM, BSE:524816 Natco Pharma Ltd.

Search Inside the pdf :

Natco Pharma Ltd.

31 May 2026

828.65

-1.15%

New launches and M&As critical to revive growth

Hold: Natco Pharma Ltd.

Recommendation Target

ICICI Securities Limited

Loss of exclusivity in gRevlimid took a toll on Natco’s Q4FY26 result, with revenue/EBITDA declining 39.5%/77.7% YoY to INR 7.3bn/INR 1.3bn, respectively.

Number of FII/FPI investors increased from 285 to 298 in Jun 2026 qtr.

Natco Pharma Ltd.

18 Mar 2026

828.65

-1.15%

NATCO PHARMA

Accumulate: Natco Pharma Ltd.

Target

Geojit BNP Paribas

We expect Natco Pharma to witness a moderation in revenue due to increased competition in Revlimid. However, the launch of generic Pomalyst and ROW opportunities are likely to partially offset this decline. Management remains focused on long-term growth, with domestic momentum expected to improve through partnerships for generic semaglutide. Additionally, the company is evaluating two potential acquisitions to further strengthen its base business. Accordingly, we...

Natco Pharma Ltd. has an average target of 1029.00 from 2 brokers.

Natco Pharma Ltd.

15 Nov 2025

828.65

-1.15%

Earnings hiccups imminent

Sell: Natco Pharma Ltd.

Recommendation Target

ICICI Securities Limited

Natco’s Q2FY26 result was ahead of our expectations, driven by higher supplies of gRevlimid which would fade away in H2FY26; management guides for profitability to drop to INR 2.75-3bn in H2 (vs. INR 10bn in H1).

Natco Pharma Ltd. is trading below all available SMAs

Natco Pharma Ltd.

17 Sep 2025

828.65

-1.15%

NATCO PHARMA

Hold: Natco Pharma Ltd.

Target

Geojit BNP Paribas

The management maintains a long-term perspective on the business, aiming to navigate potential challenges and seize growth opportunities. We anticipate a steep revenue degrowth because of lower Revlimid sales in FY27. Focus will shift on the domestic formulations business with the anticipated launches of Semaglutide, which strengthens our case for...

Number of FII/FPI investors increased from 285 to 298 in Jun 2026 qtr.

Natco Pharma Ltd.

11 Jun 2025

828.65

-1.15%

NATCO PHARMA

Hold: Natco Pharma Ltd.

Target

Geojit BNP Paribas

The company unveiled its R&D product NRC-2694 for metastatic head and neck cancer, which is currently in phase 2. The management expects to gain more clarity after a year and a half. The company currently is doing patient recruitment...